إعلان
إعلان
CVKD
Cadrenal Therapeutics, Inc. Common Stock
8.31
USDبرعاية
+0.43
+5.46%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
بعد الإغلاق
8.37
+0.05
+0.66%
تقارير أرباح CVKD
النسبة الإيجابية المفاجئة
CVKD تفوق 2 من 8 آخر التقديرات.
25%
التقرير التالي
بيانات التقرير القادم
١١ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/-$1.20
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/-8.40%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/-56.20%
Cadrenal Therapeutics, Inc. Common Stock earnings per share and revenue
On ١٠ نوفمبر ٢٠٢٥, CVKD reported earnings of -1.31 USD per share (EPS) for Q3 25, beating the estimate of -1.55 USD, resulting in a 15.87% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -3.17% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 المحللين forecast an EPS of -1.20 USD, with revenue projected to reach -- USD, implying an نقصان of -8.40% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
What were Cadrenal Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Cadrenal Therapeutics, Inc. Common Stock reported EPS of -$1.31, beating estimates by 15.87%, and revenue of $0.00, 0% as expectations.
How did the market react to Cadrenal Therapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -3.17%, changed from $12.14 before the earnings release to $11.76 the day after.
When is Cadrenal Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for ١١ مارس ٢٠٢٦.
What are the forecasts for Cadrenal Therapeutics, Inc. Common Stock's next earnings report?
Based on 5
المحللين, Cadrenal Therapeutics, Inc. Common Stock is expected to report EPS of -$1.20 and revenue of -- for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان